Deals channel feed – Endpoints News

Deals channel feed

Seagen tees up with Dutch I/O outfit, engineers $700M deal for EGFR asset

3 years ago

Armed with cash, Belgian iPSC player makes a play for Celyad’s cell therapy manufacturing site

3 years ago

Inventiva signs over China NASH rights to Sino Biopharm in possible $300M+ deal

3 years ago

Lending a hand to a biotech in trouble, GSK drops $75M cash to add late-stage antibiotic to portfolio

3 years ago

Servier cuts off collaboration agreement with Allogene on CD19 products, sending shares sputtering

3 years ago

FTC chair Lina Khan to Senate: Big Pharma M&A is still a priority target

3 years ago

Merck KGaA teams up with Italian oncology group in PARP1 development deal

3 years ago

Carisma's CAR-M steals spotlight among 42 bidders to reverse merge with Sesen Bio

3 years ago

Novo Nordisk Foundation issues $200M grant to apply quantum computing to life sciences, drug discovery

3 years ago

Swiss pharma Basilea sheds yet another oncology program as anti-infectives pivot plows forward

3 years ago

One SPAC's journey to find a partner, and its race against the clock, shows toughness of bear market

3 years ago

Renovacor ships its cardiac gene therapy to Rocket in $53M all-stock deal

3 years ago

Theravance declares independence from GSK, crafts $250M plan to buy back its own shares

3 years ago

After selling failed NASH drug to Ipsen, French startup nabs a liver disease player in small buyout

3 years ago

AmerisourceBergen throws down nearly $1.3B cash for German life sciences company

3 years ago

Novo Nordisk execs had only one drug on their mind when they came calling at Forma. Here's the inside story of their $1.1B buyout

3 years ago

MD Anderson wants to 'be part of the game,' partners with Radiopharm Theranostics for radioligand joint venture

3 years ago

Microsoft sinks deeper into drug AI, inks collab with diabetes giant Novo Nordisk

3 years ago

Imara sells failed blood disorder drug to heart disease outfit Cardurion

3 years ago

Australian CRO makes a move across the Pacific for US acquisition

3 years ago

Thanks for Nodus-ing: Basilea hands off preclinical oncology program for $248M in ongoing anti-infectives pivot

3 years ago

With first drug on the market, Arcutis forks over $16M cash for a buyout

3 years ago

#ESMO22: After day filled with investor, GSK appetite, SpringWorks brings out the data for cancer drug nearing FDA

3 years ago

Investor suit fueled by news articles over failed cancer drug ends in $24M settlement

3 years ago

First page Previous page 50 51 525354 55 56 Next page Last page